IN THE NEWS
Cardiac Science extends device connectivity to Allscripts Professional™ Electronic Health Record
Cardiac Science adds connectivity support for Allscripts EHR as part of its strategy to connect with industry-leading EHR and HIS systems« Previous Release | Next Release »
Bothell, WA – January 21, 2011 – Cardiac Science, a global leader in automated external defibrillator (AED) and diagnostic cardiac monitoring devices that connect to electronic medical record (EMR) and hospital information systems, today announced it has completed certification with Allscripts Professional EHR™. This latest certification extends its HeartCentrix cardiology device connectivity solution for its resting ECG, stress, and Holter monitoring products to support Allscripts Professional EHR for small and mid-sized physician groups. Cardiac Science previously completed certification with the Allscripts Enterprise EHR™ for large physician practices.The connectivity between Cardiac Science's equipment and the Allscripts EHRs will help physicians streamline the diagnostic cardiology workflow in their offices, eliminate a source of data transcription errors, and provide a unified view of patient diagnostic data. Through the HeartCentrix connectivity solution, physicians will have immediate access to view or edit a patient's test results electronically and later retrieve the data from the Electronic Health Record.
Dave Marver, Cardiac Science president and chief executive officer, said, “Our connectivity solution with Allscripts Professional EHR reaffirms our commitment to providing seamless connectivity with the industry’s leading EHR solutions.”
Cardiac Science connects to both Allscripts Professional and Enterprise EHR solutions via the company’s open architecture platform. As part of Allscripts ongoing commitment to open – not closed – systems, Allscripts EHRs are designed to connect to certified device vendors quickly and easily.
“Allscripts continues to lead the industry in creating open, connected systems of health by using our open architecture platform to enable third party applications and medical devices to connect to multiple Allscripts solutions,” said Allscripts Vice President of Solutions Management David Qu. “Sharing of cardiology data with a variety of Allscripts software platforms in diverse clinical settings allows our physicians to make faster, more informed decisions that ultimately result in safer patient care and better health outcomes.”
About Cardiac Science
Cardiac Science, a wholly owned subsidiary of Opto Circuits (India) Ltd., develops, manufactures, and markets a family of advanced diagnostic and therapeutic cardiology devices and systems, including automated external defibrillators (AED), electrocardiograph devices (ECG/EKG), cardiac stress treadmill and systems, PC-based diagnostic workstations, Holter monitoring systems, hospital defibrillators, vital signs monitors, cardiac rehabilitation telemetry systems, and cardiology data management systems (informatics) that connect with hospital information (HIS), electronic medical record (EMR), and other information systems. The company sells a variety of related products and consumables and provides a portfolio of training, maintenance, and support services. Cardiac Science, the successor to the cardiac businesses that established the trusted Burdick®, HeartCentrix®, Powerheart®, and Quinton® brands, is headquartered in Bothell, Washington. With customers in almost 100 countries worldwide, the company has operations in North America, Europe, and Asia. For information, call 425.402.2000 or visit http://www.cardiacscience.com.
Forward-Looking Statements
This press release contains forward-looking statements. The words "believe," "expect," "intend," "anticipate," variations of such words, and similar expressions identify forward-looking statements, but their absence does not mean that the statement is not forward-looking. Forward-looking statements in this press release include, but are not limited to, those relating to Cardiac Science Corporation's future AED sales in Japan, expected shipments of backordered products in the fourth quarter of 2010, and expectations regarding the closing of the transaction with Opto Circuits. These are forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Actual results and performance may vary significantly from those expressed or implied in such statements. Factors that could cause or contribute to such varying results and other risks include those more fully described in the Annual Report on Form 10-K filed by Cardiac Science Corporation for the year ended December 31, 2009, as updated by subsequent quarterly reports on Form 10-Q. Cardiac Science Corporation undertakes no duty or obligation to update the information provided herein.
For updates and information on worldwide defibrillation and cardiac monitoring, find us on Facebook at http://facebook.com/cardiacscience, the Cardiac Science blog at http://www.cardiacscience.com/blog, Twitter at http://twitter.com/cardiacscience, and YouTube at http://budurl.com/CSonYT
For information, contact (media) Anastasia Mironova amironova@cardiacscience.com+1.425.402.2092 | (investors) ir@optoindia.com | +91.80.2852.8088 LOGO: http://www.cardiacscience.com/images/main_logo.gif